| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
UNC3230 is a selective inhibitor of lipid kinase PIP5K1C. It acts by lowering PIP2 levels in DRG neurons and attenuating hypersensitivity.
| ln Vitro |
When compared to vehicle control, membrane PIP2 levels in dorsal root ganglion (DRG) neurons treated with 100 nM UNC3230 (~2x the IC50) were significantly lower by about 45%. In DRG neurons, UNC3230-cultured cultures considerably inhibited lysophosphatidic acid (LPA)-evoked calcium signaling in comparison to vehicle cultures [1].
|
|---|---|
| ln Vivo |
Two hours after intrathecal injection into wild-type mice, UNC3230 (2 nmol) dramatically enhances the heat-induced paw withdrawal latency of pests, indicating an anti-inflammatory impact [1]. UNC3230 (2 nmol; intrathecal), then co-injecting 1 nmol LPA with UNC3230 (2 nmol, intrathecal) one hour later. When compared to a car, UNC3230 dramatically reduces mechanical allodynia and thermal hyperalgesia [1]. Thermal hyperalgesia and mechanical allodynia are greatly reduced by UNC3230 (2 nmol; intrathecally) [1]. Over the course of many days, the adjuvant (CFA)-inflamed hindpaw showed both mechanical allodynia and thermal hyperalgesia in comparison to the control, but neither the thermal nor the mechanical texture of the non-inflamed hindpaw was impacted [1].
|
| References |
|
| Molecular Formula |
C17H20N4O2S
|
|---|---|
| Molecular Weight |
344.43
|
| Exact Mass |
344.13
|
| Elemental Analysis |
C, 59.28; H, 5.85; N, 16.27; O, 9.29; S, 9.31
|
| CAS # |
1031602-63-7
|
| Related CAS # |
1031602-63-7;
|
| PubChem CID |
46355372
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.687
|
| LogP |
2.49
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
450
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N)C=1NC(SC1NC(C2CCCCC2)=O)=NC3=CC=CC=C3
|
| InChi Key |
RZCNASHHHSKTGP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H20N4O2S/c18-14(22)13-16(21-15(23)11-7-3-1-4-8-11)24-17(20-13)19-12-9-5-2-6-10-12/h2,5-6,9-11H,1,3-4,7-8H2,(H2,18,22)(H,19,20)(H,21,23)
|
| Chemical Name |
5-(Cyclohexanecarboxamido)-2-(phenylamino)thiazole-4-carboxamide
|
| Synonyms |
UNC3230 UNC-3230 UNC 3230
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~362.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9033 mL | 14.5167 mL | 29.0335 mL | |
| 5 mM | 0.5807 mL | 2.9033 mL | 5.8067 mL | |
| 10 mM | 0.2903 mL | 1.4517 mL | 2.9033 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
